October 23, 2013 09:29 ET

NovaBay CFO Discusses Antibiotic Resistance Efforts in CEONews.Tv Interview

Tom Paulson Discusses Results of Phase 2 Clinical Trial of Auriclosene®

NEW YORK, NY--(Marketwired - Oct 23, 2013) - CEONews.Tv announced today that NovaBay Pharmaceuticals, Inc.'s (NYSE MKT: NBY) ("NovaBay") (, an advanced clinical-stage biopharmaceutical company CFO Thomas "Tom" Paulson is featured in an interview entitled "Going Beyond Antibiotics" with Charles Sample II. Topics discussed included its Aganocide® auriclosene and its use in treatments for Urinary Catheter Blockage and Encrustation (UCBE), Impetigo, and Viral Conjunctivitis. For the full interview please visit:

Interview highlights include:

  • NovaBay is addressing the large unmet therapeutic needs of the global, topical anti-infective market with its Aganocide® compounds, led by auriclosene ( Auriclosene is a new chemical entity invented by NovaBay which has a broad spectrum of activity against bacteria, viruses and fungi.
  • Aganocide compounds are based on the human body's natural immune system and the molecules involved in combating infections. Bacterial resistance to Aganocides is highly unlikely, as demonstrated in in vitro studies. Once pathogens penetrate the body's primary defense, the next line of defense is provided by the white blood cells. NovaBay has focused on understanding these molecules generated by the white blood cells and finding ways, by chemical modification, to allow them to be developed as therapeutic products with the potential to treat a wide range of local, non-systemic infections. As Aganocides begin to supplement and thereby reduce the usage of classic topical antibiotics, they will help slow the rise of antibiotic resistance*.

When asked about treating patients that experience the chronic condition of Urinary Catheter Blockage and Encrustation (UCBE: Paulson stated that NovaBay announced results from its Phase 2 clinical study CL1001 for auriclosene (NVC-422) to prevent UCBE of indwelling urinary catheters. The results of the study showed that NovaBay's auriclosene-based irrigation solution has demonstrated the ability to mitigate an important medical problem, cut healthcare costs, and improve the quality of life for tens of thousands of patients in the U.S. alone. Based on these study results, the Company plans to continue discussions with the FDA and move toward registration. A catheter irrigation solution that significantly reduces catheter blockage and encrustation could greatly reduce the estimated $1 billion spent annually to help patients with indwelling urinary catheters deal with costs attributable to this debilitating condition. Such a product would also improve the quality of patients' lives by reducing the consequences of unexpected catheter blockages.

* For a more complete overview of the "Antibiotic Resistance" Crisis in America visit Frontline® at:

About CEONews.Tv:
CEONews.Tv is an online market news and mobile news provider that brings investors -- Big News For The SmallCap Market!™. CEONews.Tv offers platforms that allow CEOs, CFOs, COOs, Presidents and Directors of companies to deliver answers to the questions that investors would like asked. Through these mediums Executives share their insights, accomplishments, current projects, daily challenges they face and the future goals and aspirations they have for the companies that they lead. For further information please visit To have Your Company Interviewed please send an email request to: or call 765.CEO.NEWS (236-6397).

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions relating to NovaBay's future business prospects and clinical trials. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. In addition, description of anyone's past success, either financial or strategic, is not a guarantee of future success. This news release speaks as of the date first set forth above and neither CEONews.Tv or the interviewed company assumes any responsibility to update the information included herein for events occurring after the date hereof.

Contact Information